In particular, the 1-benzyl-3,5-bis((E)-3-bromobenzylidene)piperidin-4-one 3 behaved as dual p300/EZH2 inhibitor and displayed cancer-selective growth arrest and cell death in hematological malignancies as well as solid tumors, in in vitro, ex vivo, and in vivo models [21,22]. This evidence concerns the gene EP300 and hematologic disorder.